Skip to main content
. 2023 Nov 15;10:1256712. doi: 10.3389/fmed.2023.1256712

Figure 3.

Figure 3

Forest plots displaying the weighted mean differences of HAQ-DI at 12 months, relative to baseline: (A) in RCTs of participants with RA treated with adalimumab; (B) in longitudinal cohorts of participants with RA treated with adalimumab.